$Inhibikase Therapeutics (IKT.US)$ learn from $Amedisys (AME...
$Inhibikase Therapeutics(IKT.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
learn from
$Amedisys(AMED.US$
$AMC Entertainment(AMC.US$
$Fulcrum Therapeutics(FULC.US$
JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
